Development of an automated RNA-based nuclease protection assay for the detection of expressed EML-ALK fusions, EGFR, and KRAS mutations in NSCLC. This is an ASCO Meeting Abstract from the 2013 ASCO ...
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has won U.S. Food and Drug Administration approval for RYBREVANT FASPRO, the ...
Docetaxel (D) versus docetaxel/gemcitabine (D&G) in the treatment of older patients with advanced non-small cell lung cancer (NSCLC): An Alpe Adria Thoracic Oncology Multidisciplinary Group randomized ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
The U.S. Food and Drug Administration (FDA) have granted approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), ...
Papulopustular eruptions are the most common cutaneous adverse effect of epidermal growth factor receptor (EGFR) inhibitors, typically arising within the first month of therapy. We describe an unusual ...
Lung cancer is the second most common cancer after breast cancer in women, after prostate cancer in men, and is the leading cause of cancer-related deaths worldwide. The proportion of lung cancer ...
In a study comparing the effect of 9 oral nonsteroidal anti-inflammatory drugs on kidney function, ibuprofen conferred the lowest risk for incident eGFR less than 60 mL/min/1.73 m2 and an eGFR decline ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback